| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8275360 | Journal of the Neurological Sciences | 2015 | 7 Pages |
Abstract
HCQ treatment reduces the activation of human microglia in vitro, delays the onset of EAE, and decreases the representation of activated macrophages/microglia and demyelination in the spinal cord of treated mice. HCQ is a plausible candidate for further clinical studies in MS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Marcus W. Koch, Rana Zabad, Fabrizio Giuliani, Walter Jr., Ray Lewkonia, Luanne Metz, V. Wee Yong,